Categories
Corticotropin-Releasing Factor, Non-Selective

IgM testing can aid earlier diagnoses if used within a selective two-tier screening protocol: only patients with acute onset of symptoms should be tested for IgM CLIA but confirmation by immunoblot and consideration of clinical picture is necessary

IgM testing can aid earlier diagnoses if used within a selective two-tier screening protocol: only patients with acute onset of symptoms should be tested for IgM CLIA but confirmation by immunoblot and consideration of clinical picture is necessary. sensu lato (hereafter was introduced in 2018, followed by the introduction of IgM (and IgG) chemiluminescent immunoassay (CLIA) in 2020. Methods to detect IgG antibodies to lack sensitivity during early disease, and their persistence in serum can complicate interpretation [3C8]. concern of clinical picture is necessary. sensu lato (hereafter was launched in 2018, followed by the introduction of IgM (and IgG) chemiluminescent immunoassay (CLIA) in 2020. Methods to detect IgG antibodies to lack sensitivity during early disease, and their persistence in serum can complicate interpretation [3C8]. Although IgM antibodies are produced earlier than IgG, studies found that IgM assessments have suboptimal specificity with high false positive rates due to cross-reactions with other infections and autoantibodies [9C11]. IgM may also persist [12, 13]. The aim of this study was to evaluate the benefits and limitations of both CLIA and immunoblot for the detection of IgM antibodies to for the laboratory diagnosis of patients with acute LB. Methods Data for serum samples sent from throughout Scotland and tested at the Scottish Lyme Disease and Tick-Borne Infections Reference Laboratory (SLDTRL) for antibodies from 1 June 2018 to 17 October 2020 were analysed: (i) Sera from 01/06/2018 to 14/04/2020 were tested by Enzygnost Lyme-link VlsE/IgG ELISA (Siemens) around the DS2 platform (Launch) following the manufacturers instructions. Equivocal or positive sera were subsequently tested by Borrelia recomLine IgG and IgM immunoblot (Mikrogen) around the CarL immunoblot platform (Mikrogen) and the results interpreted as per the manufacturers instructions. Samples that were IgM immunoblot positive and IgG immunoblot unfavorable or equivocal were recognized for further analyses. (ii) Sera from 15/04/2020 to 17/10/2020 were tested by DiaSorin Borrelia IgG and IgM Quant Abarelix Acetate CLIA around the Liaison XL analyser following discontinuation of the Enzygnost ELISA. Any samples that were positive or equivocal by Alizapride HCl either assay were tested by IgG and IgM immunoblot as above. Samples that were IgG CLIA unfavorable and IgM CLIA reactive (positive/equivocal), IgM immunoblot positive and IgG immunoblot unfavorable or equivocal were recognized for further analyses. Clinical information from specimen request forms, additional information from questionnaires returned from your referring clinician and any data from subsequent samples were used to allocate individual patients with isolated IgM results into groups based on likelihood of acute LB (Table ?(Table11). Table 1 Patient groups and selection criteria for samples with isolated IgM results Alizapride HCl assays lack inter-assay consensus, particularly IgM assays [21, 22]. Interestingly, one of these studies calculated that a small loss of specificity led to an additional 192,716 immunoblot assessments required (4,625,183 Euros), with an additional 6191 IgM false positive results. Due to the issues layed out above, some countries have, or are considering, stopping the use of IgM screening for LB. However, some cases of early disease may be missed and patient confidence in screening regimes will undoubtedly be affected, which could further gas the controversy around screening. Some manufacturers claim that IgG antibodies to the VlsE antigen of can be detected prior to or parallel to the formation of IgM antibodies and are more specific than IgM assays; thus, the use of VlsE/IgG screening assays is sufficient. However, the IgG CLIA used in this study, which contains the VlsE antigen, missed some cases of acute LB. Although complex to implement in laboratories with a high throughput of specimens, perhaps the use of selective screening protocols would be optimal, utilising IgM CLIA only for those patients with an acute onset of specific symptoms within a two-tier screening protocol. Author contribution GJ: screening, data analysis and initial draft preparation. SM: conceptualization, supervision, review, editing and redraft preparation. RM: screening, review Alizapride HCl and editing. CL: review and editing, clinical expertise. Funding This research was supported as part of Northtick, an Interreg project supported by the North Sea Programme of the European Regional Development Fund of the European Union. SM is a member of ESGBOR. Data availability N/A Code availability N/A Declarations Ethics approvalN/A Consent to participateN/A Consent for publicationN/A Discord of interestThe authors declare no competing interests. Footnotes Publishers note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations..